Botswana Blood Products Import Market -- HS Code 3002 Trade Data & Price Trend (Jul 2025)

Botswana Blood Products Import (HS 3002) Key Takeaways

Botswana's July 2025 blood products import market (HS code 3002) is dominated by bulk veterinary vaccines and high-value finished pharmaceuticals, reflecting a dual demand from agriculture and healthcare sectors. The market shows volatile recovery, with imports rebounding to $1.42 million after a sharp April decline linked to new tariffs. Supply chain risk is high, with over 96% of imports controlled by a single supplier group and South Africa providing 55% of bulk volume. Pricing power lies with finished product suppliers, while bulk traders face cost competition. This analysis covers July 2025 and is based on cleanly processed customs data from the yTrade database.

Botswana Blood Products Import (HS 3002) Background

What is HS Code 3002?

HS Code 3002 covers human and animal blood products, vaccines, toxins, and cultures. These products are critical for pharmaceuticals, medical research, and public health initiatives, driving consistent global demand. Their trade is tightly regulated due to safety and efficacy concerns, making compliance a key market driver.

Current Context and Strategic Position

The United States recently increased additional duties on all imports from Botswana to 37%, effective April 2025 [Global Trade Alert]. This policy shift could disrupt Botswana's blood products import trade, particularly for HS Code 3002 goods. Botswana's strategic role in this trade flow stems from its reliance on imported medical supplies to meet domestic healthcare needs. Monitoring hs code 3002 trade data is now essential to assess the impact of these tariffs and ensure supply chain resilience. Market vigilance is critical as Botswana navigates these evolving trade dynamics.

Botswana Blood Products Import (HS 3002) Price Trend

Key Observations

In July 2025, Botswana's blood products imports under HS code 3002 reached a value of $1.42 million USD, with a unit price of $65.78 per kg. This represents a recovery from the previous month's low, highlighting the Botswana Blood Products Import trend's inherent volatility.

Price and Volume Dynamics

The hs code 3002 value trend exhibited significant fluctuations in 2025, peaking at $3.86 million USD in March before declining sharply in April. This volatility aligns with the implementation of new tariff rate quotas for imports from MERCOSUR countries, which took effect in January and likely disrupted supply patterns [BURS]. The sequential rebound in July—with value doubling from June and volume rising markedly—suggests market adaptation to these policy changes, possibly through diversified sourcing or inventory restocking to meet steady healthcare demand.

Botswana Blood Products Import (HS 3002) HS Code Breakdown

Product Specialization and Concentration

Botswana's July 2025 import market for HS Code 3002 is heavily concentrated in veterinary vaccines, which account for over one-third of the total import value. According to yTrade data, this product group, described as vaccines and similar products for veterinary medicine, was the most frequently traded and had the largest share by weight. Its relatively low unit price of 47 US dollars per kilogram suggests it is imported in bulk, forming the volume backbone of Botswana's HS Code 3002 trade data. One extreme price anomaly was noted for a small volume of human vaccines at over 4,385 US dollars per unit, which is excluded from the main analysis pool.

Value-Chain Structure and Grade Analysis

The remaining imports break into two clear value tiers. The first is mid-value blood fractions and antisera, with a unit price around 58 US dollars per kilogram, representing another major volume segment. The second is high-value, finished immunological products packaged for retail sale, which command a premium unit price exceeding 800 US dollars per kilogram despite a small physical volume. This structure shows Botswana's import of HS Code 3002 blends bulk, commodity-like biologicals with high-value, differentiated finished goods, indicating a market that serves both agricultural and healthcare sectors.

Strategic Implication and Pricing Power

For businesses involved in Botswana's import of HS Code 3002, pricing power clearly resides with suppliers of finished, retail-ready immunological products due to their high value density. Companies supplying bulk veterinary or blood products will face stronger competition on cost. Strategic focus should target the high-margin retail segment or ensure cost leadership in bulk supply to compete effectively within this trade flow.

Table: Botswana HS Code 3002) Breakdown Details (Source: yTrade)

Check Detailed HS Code 3002 Breakdown

Botswana Blood Products Import (HS 3002) Origin Countries

Geographic Concentration and Dominant Role

South Africa is the dominant source for Botswana's Blood Products imports in July 2025. It supplied over half (55.03%) of the total weight but only 30.30% of the total value. This large gap, where the weight share is much higher than the value share, points to shipments of bulk, lower-value raw materials or intermediate goods within the blood product supply chain. South Africa also accounted for nearly half (49.68%) of all import transactions, indicating a high-frequency, routine supply relationship.

Origin Countries Clusters and Underlying Causes

Import partners form two clear clusters. The first is a High-Yield Cluster, including the United Kingdom, India, Ireland, and Switzerland. These countries have high value shares (11.64% to 16.21%) but very low weight shares (0.05% to 15.20%), signaling imports of high-value, finished pharmaceutical products. The second is a Volume Cluster, consisting of the United States and Spain. They show more balanced value-to-weight ratios, suggesting shipments of standardized, mid-value products. New Zealand and Austria are outliers with unit prices that are physical impossibilities for this product category, so their volume data is not considered reliable for this share analysis.

Forward Strategy and Supply Chain Implications

Botswana's blood product supply chain is highly dependent on South Africa for bulk raw materials, creating a concentration risk. The sourcing strategy should focus on diversifying bulk suppliers to mitigate potential disruptions. The role of the United States as a volume supplier was likely impacted by a 37% additional duty on all imports from Botswana that was enacted in April 2025 [GlobalTradeAlert], which may have reduced two-way trade flows. Maintaining partnerships with high-yield countries remains crucial for securing specialized, finished blood products that are not produced domestically.

Table: Botswana Blood Products (HS 3002) Top Origin Countries (Source: yTrade)

Get Complete Origin Countries Profile

Botswana Blood Products (HS 3002) Suppliers Analysis

Supplier Concentration and Dominance

According to yTrade data, the Botswana Blood Products Import supplier market in July 2025 is highly concentrated. One group of suppliers dominates, handling over 96% of the total import value. This group also accounts for nearly all the volume and weight shipped. A typical trade involves large, frequent shipments of high-value goods.

Strategic Supplier Clusters and Trade Role

The dominant suppliers are manufacturers like ROCHE. This points to a direct-to-factory sourcing model for HS code 3002 goods. A smaller cluster of suppliers handles lower-value items but still ships regularly. These firms, such as proficiency testing providers, support ancillary needs but do not drive core supply.

Sourcing Strategy and Vulnerability

Botswana's blood product imports rely heavily on one key supplier type. This creates vulnerability to supply chain shocks or cost changes. The recent U.S. tariff increase on all imports from Botswana [globaltradealert.org] adds cost pressure. Diversifying suppliers could reduce risk.

Table: Botswana Blood Products (HS 3002) Top Suppliers List (Source: yTrade)

Check Full Blood Products Supplier lists

Action Plan for Blood Products Market Operation and Expansion

• Analyze Botswana's Blood Products Import data to identify and qualify secondary suppliers in the EU and India, reducing over-reliance on South Africa for bulk veterinary vaccines and mitigating supply chain disruption risks.
• Use hs code 3002 trade data to monitor unit prices and shipment frequencies, targeting high-margin finished immunological products to improve profit margins despite higher import costs from premium suppliers.
• Diversify the Blood Products supply chain by sourcing from countries like Ireland and Switzerland for high-value antisera, ensuring access to critical specialized products not available domestically.
• Adjust procurement strategies for hs code 3002 trade flows to account for U.S. tariff impacts, prioritizing cost-efficient partners in non-affected regions to maintain budget control and supply continuity.
• Implement real-time trade data tracking for all HS Code 3002 imports, enabling rapid response to price shifts or supplier issues and safeguarding Botswana's healthcare and agricultural sectors from volatility.

Take Action Now —— Explore Botswana Blood Products Import Data

Frequently Asked Questions

Q1. What is driving the recent changes in Botswana Blood Products Import 2025 July?

The recovery in July 2025 follows sharp volatility earlier in the year, likely due to tariff disruptions and subsequent market adaptation. The rebound reflects restocking efforts and diversified sourcing to meet steady healthcare demand.

Q2. Who are the main origin countries of Botswana Blood Products (HS Code 3002) 2025 July?

South Africa dominates with 55% of the weight and 30% of the value, while the UK, India, Ireland, and Switzerland form a high-value cluster contributing 11–16% of value each but minimal weight.

Q3. Why does the unit price differ across origin countries of Botswana Blood Products Import?

Prices vary due to product specialization: bulk veterinary vaccines and raw materials (e.g., from South Africa) cost under $60/kg, while retail-ready immunological products (e.g., from the UK or Switzerland) exceed $800/kg.

Q4. What should importers in Botswana focus on when buying Blood Products?

Importers should prioritize diversifying bulk suppliers (e.g., beyond South Africa) to mitigate concentration risks while securing high-margin finished products from premium markets like Switzerland or Ireland.

Q5. What does this Botswana Blood Products import pattern mean for overseas suppliers?

Suppliers of retail-ready products have strong pricing power, while bulk suppliers face cost competition. The U.S. tariff hike on Botswana-bound goods has likely reduced trade opportunities for mid-tier volume suppliers.

Q6. How is Blood Products typically used in this trade flow?

Imports serve dual sectors: bulk veterinary vaccines support agriculture, while high-value blood fractions and retail immunological products cater to healthcare needs.